You are here

Drug-drug interactions in older patients with cancer: a report from SIOG 2015 annual conference

Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015 was published on the ecancer website.

Given the potential for drug-drug interactions (DDIs) in elderly cancer patients, it was appropriate and helpful for the recent 15th Conference of the International Society of Geriatric Oncology (SIOG), held in Prague, Czech Republic in November 2015 to devote a plenary session to this topic. It was chaired by Stuart Lichtman (Memorial Sloan Kettering Cancer Centre, Commack, New York, USA) and Romano Danesi (Department of Clinical and Experimental Medicine, University of Pisa, Italy).

Abstract of the report

Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic window of cytotoxics, but the metabolism of tyrosine kinase inhibitors by the cytochrome P450 3A4 enzyme (CYP3A4) makes some TKIs particularly prone to interference with or from other agents sharing this pathway. There is also potential for adverse pharmacokinetic interactions with new hormonal agents used in advanced prostate cancer...Read more

Plenary session

A plenary session on this topic was held on Friday, November 13, 2015 duirng the SIOG 2015 annual conference.
Drug drug interaction in older cancer patients
Chairs: Romano Danesi (IT) and Stuart Lichtman (US)
14:00-14:15 Polypharmacy: implications in the elderly - Holly Holmes (US)
14:15-14:30 Examples of existing resources to learn about DDI - Vincent Launay-Vacher (FR)
14:30-14:45 Oncology and supportive care drugs with frequent DDI issues - Stuart Lichtman (US)
14:45-14:50 Questions and answers
14:50-15:05 Prostate cancer, new drugs and DDI - Kurt Miller (DE)
15:05-15:20 Profiling the DDI aspects of drugs in prostate cancer - Romano Danesi (IT)
15:20-15:30 Questions and answers


The webinar from the plenary session can be watched here.
The session and this webcast were supported by an unrestricted grant by Janssen.